Latest Flovent News

Mylan Inks Two Separate Agreements Flixotide and Flovent are approved for the treatment of asthma and had global brand sales of around $ 1.3 billion...


Mylan Inks Two Separate Agreements
Flixotide and Flovent are approved for the treatment of asthma and had global brand sales of around $ 1.3 billion in 2013 as per IMS Health. As per the terms of the agreement, Mylan will gain marketing rights for PSX1001 and PSX1050 in the U.S., Canada, …
Read more on Zacks.com

Leave a Reply